1. Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract Cancer
   Amanda N. Ruggieri et al, 2022, Clinical Cancer Research CrossRef
2. Growth factors
   Gerald Litwack, 2022, Hormones CrossRef
3. Advancements in precision nanomedicine design targeting the anoikis-platelet interface of circulating tumor cells
   Manqing Tang et al, 2024, Acta Pharmaceutica Sinica B CrossRef
4. Emerging roles of platelets in cancer biology and their potential as therapeutic targets
   Lei Wang et al, 2022, Frontiers in Oncology CrossRef
5. Role of Mechanotransduction in Periodontal Homeostasis and Disease
   M.P. Dieterle et al, 2021, Journal of Dental Research CrossRef
6. Pancreatic Cancer and Platelets Crosstalk: A Potential Biomarker and Target
   Shaoshan Mai et al, 2021, Frontiers in Cell and Developmental Biology CrossRef
7. Exploring the Link between Inflammatory Biomarkers and Head and Neck Cancer: Understanding the Impact of Smoking as a Cancer-Predisposing Factor
   Jarosław Nuszkiewicz et al, 2024, Biomedicines CrossRef
8. From the Matrix to the Nucleus and Back: Mechanobiology in the Light of Health, Pathologies, and Regeneration of Oral Periodontal Tissues
   Martin Philipp Dieterle et al, 2021, Biomolecules CrossRef
9. PDGFRβ targeted innovative imaging probe for pancreatic adenocarcinoma detection
   Xin Gao et al, 2023, Talanta CrossRef
10. Targeting anoikis resistance as a strategy for cancer therapy
    Yumin Wang et al, 2024, Drug Resistance Updates CrossRef
11. Targeting the PDGF/PDGFR signaling pathway for cancer therapy: A review
    Xiang Zou et al, 2022, International Journal of Biological Macromolecules CrossRef
12. Conquering chemoresistance in pancreatic cancer: Exploring novel drug therapies and delivery approaches amidst desmoplasia and hypoxia
    Pavan Kumar Chintamaneni et al, 2024, Cancer Letters CrossRef
13. Bidirectional Interaction Between Cancer Cells and Platelets Provides Potential Strategies for Cancer Therapies
    Liuting Yu et al, 2021, Frontiers in Oncology CrossRef
14. Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma
    Rita Rebelo et al, 2021, Pharmaceuticals CrossRef
15. Stearoyl-CoA desaturase 1 inhibitor supplemented with gemcitabine treatment reduces the viability and fatty acid content of pancreatic cancer cells in vitro
    Amon B. Hackney et al, 2021, Journal of Pancreatology CrossRef
16. Programming Affinity for Precise Tumor Recognition with Allosteric Nanosensing-Circles
    Lili Ai et al, 2023, ACS Nano CrossRef
17. Mechanisms for Modulating Anoikis Resistance in Cancer and the Relevance of Metabolic Reprogramming
    Funmilayo O. Adeshakin et al, 2021, Frontiers in Oncology CrossRef
18. F-Box and Leucine-Rich Repeat Protein 20 (FBXL20), Negatively Regulated by microRNA (miR)-195-5p, Accelerates the Malignant Progression of Ovarian Cancer
    Debin Wu et al, 2021, Molecular Biotechnology CrossRef
19. Emerging kinase inhibitors for the treatment of pancreatic ductal adenocarcinoma
    Udo Rudloff, 2022, Expert Opinion on Emerging Drugs CrossRef
20. Targeting Growth Factor Signaling Pathways in Pancreatic Cancer: Towards Inhibiting Chemoresistance
    Ntombikayise Xelwa et al, 2021, Frontiers in Oncology CrossRef
21. BAG6 restricts pancreatic cancer progression by suppressing the release of IL33-presenting extracellular vesicles and the activation of mast cells
    Bilal Alashkar Alhamwe et al, 2024, Cellular & Molecular Immunology CrossRef
22. Challenges and Opportunities Associated With Platelets in Pancreatic Cancer
    Zhou Chen et al, 2022, Frontiers in Oncology CrossRef
23. The role of tumor-platelet interplay and micro tumor thrombi during hematogenous tumor metastasis
    Qianyu Shi et al, 2023, Cellular Oncology CrossRef